Core Insights - ASUS has launched a series of significant discounts for Amazon Prime Day, offering savings of up to $700 and discounts reaching 53% on various products from July 8 to July 11 [3][6]. Everyday Laptops - ASUS Zenbook A14: Originally priced at $1,399, now available for $1,229, saving $170. Features include a Snapdragon® X Processor, up to 32 hours of battery life, and a lightweight design [3]. - ASUS Vivobook S14 Flip: Priced down from $1,299 to $949, saving $250. This 2-in-1 laptop includes an Intel® Core™ i7-13620H processor, 1TB SSD, and 16GB RAM [4]. - ASUS Vivobook Go 15: Reduced from $799 to $549, saving $250. It features a 15.6-inch Full HD display and AMD Ryzen™ 5 7520U processor [5]. - ASUS Vivobook S15: Now $949.99, down from $1,499, saving $549. It is powered by the Snapdragon® X Elite processor and features a 15.6" 3K 120Hz OLED display [5]. Gaming Laptops - TUF Gaming A15: Priced at $1,299, down from $1,799, saving $500. It features an AMD Ryzen™ 9 8945HS processor and NVIDIA® GeForce RTX™ 4060 GPU [7]. - TUF Gaming F17: Now $1,599, reduced from $2,299, saving $700. It includes a 17.3" FHD display and Intel® Core™ i9 processor [7]. - ROG Strix G16 (2024): Available for $1,599, down from $1,999, saving $400. It features an Intel® Core™ i7-13650HX processor and NVIDIA® GeForce RTX™ 4060 GPU [8]. - ROG Strix G18 (2025): Priced at $3,499, down from $3,799, saving $300. It includes an Intel® Core™ Ultra 9 Processor and NVIDIA® GeForce RTX™ 5070Ti GPU [8]. Chromebooks - ASUS Chromebook CX14: Now $229, down from $369, saving $140. It features an Intel Processor N4500 and a Full HD NanoEdge display [9]. - ASUS Chromebook CX1: Reduced from $399 to $189, saving $210, which is a 53% discount. It features a 15.6-inch Full HD display and military-grade durability [9]. - ASUS Chromebook Plus CX15: Now $349, down from $499, saving $150. It features an Intel® Core™ i3 processor and enhanced productivity tools [9]. Desktops & All-in-Ones - ASUS V440 All-in-One: Priced at $599, down from $899, saving $300. It features an Intel® Core™ i3-1315U processor [11]. - ASUS ExpertCenter P500: Now $649, reduced from $899, saving $250. It features an Intel® Core™ i5-13420H processor and is designed for business use [12].

据《华夏时报》记者统计，截至目前，和铂医药已完成17次BD出海交易，成为国内BD出海交易数量最 多的药企。同时，公司正在业绩波动、研发投入持续萎缩及与百奥赛图的专利纠纷渐入关键阶段的多重 挑战中寻找平衡。尽管2024年营收与净利润同比大幅下滑，研发费用缩水超五成，但公司BD合作的节 奏并未放缓——2025年上半年已达成5笔BD交易。这家以BD模式为核心的创新药企，正站在业绩稳定 性与技术护城河的双重考验路口。 BD依赖下的收入震荡 作为国内极少数未实现产品商业化却能依靠BD业务连续盈利的生物技术公司，和铂医药的收入几乎完 全依赖BD业务。2024年，公司录得收入3810万美元，同比下降57.43%；年内溢利为274.2万美元，较上 年同期2276.3万美元下降87.95%。尽管业绩出现大幅收缩，但仍延续了盈利态势，实现连续两年盈利。 近日，港股创新药企和铂医药公告披露，与日本大塚制药达成全球战略合作。协议显示，和铂医药将其 用于治疗自身免疫疾病的BCMAxCD3双特异性T细胞衔接器（TCE）HBM7020在大中华地区以外的全 球开发、制造及商业化权益授予大塚制药，借此获得4700万美元首付款及近期付款，叠加最 ...

2 July 2025 | 4:24PM HKT WuXi Biologics (2269.HK): China Healthcare Corporate Day 2025 — Key Takeaways: on-track to deliver revenue guidance; capacity We hosted WuXi Biologics's IR team with investors (virtual) on Jul 2 at our China Healthcare Corporate Day 2025. Bottom line: Mgmt noted 1) on track to deliver FY25 revenue guidance (+12-15% y/y, or +17-20% y/y for continuing operations), supported by robust BD (business development) momentum and healthy new client order; 2) Leading biotech & pharma clients i ...

每经记者｜鄢银婵 每经编辑｜张海妮 今年以来，国内创新药颇有久旱逢甘霖之势，而撬动这一局面的关键杠杆是频繁刷屏的"BD"。 BD，即商务拓展（Business Development），是一种通过对外授权实现研发变现的合作模式。简单来说，BD是药企将自主研发的创新药权益授权给跨国药 企，以换取首付款、里程碑付款及销售分成，这一模式既能缓解资金压力，又能借助国际巨头的渠道加速产品全球化进程。 近期，一家专注于双特异性T细胞衔接器（TCE双抗）的Biotech（生物科技）公司——岸迈生物科技有限公司（以下简称岸迈生物）冲刺港股IPO（首次公 开募股），引发市场关注。这家公司在业内早已因BD交易声名鹊起：自2023年底以来，其通过多项授权合作累计斩获超21亿美元交易价值，在TCE双抗领 域全球交易额排名第二。 值得注意的是，岸迈生物与近期创下中国创新药授权纪录的三生制药存在渊源。其创始人吴辰冰曾担任三生制药首席科学官兼研发总裁。这种技术传承与资 本路径的交织，也折射出中国创新药企从"跟随"到"输出"的转型逻辑。 岸迈生物IPO或许将成为观察中国Biotech成色的新窗口。招股书（申报稿）显示，截至2024年底，公司 ...

Core Insights - Tevogen Bio Holdings Inc. emphasizes the significance of AI in drug discovery and has made a substantial investment in its new corporate headquarters [1][2] - The new facility will enhance collaboration among cross-functional teams and support the development of Tevogen's AI platforms [2][3] - The CEO's personal investment reflects strong leadership conviction in the company's mission and long-term vision for affordable cell therapies [3] Company Developments - The CEO, Ryan Saadi, M.D., M.P.H., contributed $500,000 for the build-out and first-year operating costs of the new headquarters in Warren, New Jersey [1] - The new facility more than doubles the previous operational footprint and centralizes various teams, including research and regulatory affairs [2] - The dedicated collaboration spaces are designed to facilitate the work of data scientists and engineers on Tevogen's proprietary AI platforms, PredicTcell™ and AdapTcell™ [2] Financial Outlook - The CFO, Kirti Desai, highlighted that the CEO's investment underscores the leadership's commitment to capital discipline while enabling efficient scaling [3]

投资是认知的表现，亮眼的业绩背后是对投资深刻的认知。在医药投资上，桑翔宇有着独特的见解和成 熟的体系，他认为要从从自上而下和自下而上两个维度进行。 从自上而下的角度来看，医药行业受政策影响很大，要对政策有深刻的理解，这是做好医药投资的关 键。除政策因素外，创新药的投资还要把握好产业周期和技术周期的位置。从自下而上的角度来看，主 要关注以下几个方面：首先，企业家的品质和管理水平是核心，这是所有DCF假设是否能够兑现的关 键；其次，要对创新药公司的业务储备管线有深入了解；再其次，要抓住行业或公司的主要矛盾；最 后，要动态跟踪行业层面和个股层面的变化，包括报表数据和产品临床数据的推进等。 今年以来，创新药板块表现抢眼，华安基金桑翔宇把握住了机会，他管理的华安医药生物基金，业绩表 现非常突出。这只去年底成立的基金，最新净值达1.7元左右。现在市场最关心的是，在近期调整之 后，创新药板块将如何演绎？ 在桑翔宇看来，当前的创新药行业，正在迎来政策面、产业面、技术面和基本面这四重利好共振，这将 是以年为维度的重大投资机会，当前要坚定信心，迎接创新药投资的黄金时代。 精准出击九年深耕厚积薄发 九年深耕，一朝绽放。 从华安医药 ...

"传统新药研发模式存在投入大、风险高的特点，从资本回报率角度看并不划算。基于此，头部国际药 企调整策略，不再单纯依赖自主研发，而是通过与创新药企业建立合作机制，在合作方研发项目取得关 键阶段性成果后实施收购，以此大幅降低药物研发的系统性风险。"乐嵘说。 浙商证券生物医药行业分析师郭双喜认为，当前，医药跨国公司均有不错的一代肿瘤免疫治疗 转自：新华财经 新华财经北京6月24日电（记者闫鹏）在经过一周的调整之后，创新药板块"王者归来"。24日收盘，港 股创新药ETF（159567）、创新药ETF（159992）分别上涨2.25%、1.15%。截至发稿时，荣昌生物A股 股价当日收涨6.38%，荣昌生物H股股价涨逾13%，绿叶制药H股股价涨逾9.5%，康诺亚-B H股股价涨逾 6%，亚盛医药-B H股股价涨逾6%、康哲药业H股股价涨逾5%。 业内人士认为，中国创新药产业迎来黄金发展期，此轮行情的核心驱动力在于BD（商务拓展）交易活 跃。在潜力大单品、政策利好持续驱动下，预计从今年中报开始创新药企收入将迎集体改善，中国创新 药企估值也将持续重塑。 国内创新药"出海"BD激增 6月23日，和铂医药发布公告称，公司与日本制 ...

WARREN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today provided an update on its ongoing development of a cytotoxic T lymphocyte (CTL) therapy targeting Epstein-Barr virus (EBV)-associated lymphomas. Computer-based selection of EBV peptides is currently underway as part of Tevogen's preparation for a potential clinical trial using EBV-specific CTLs manufactured using the Company's proprietary ExacTcell™ technology. ExacTcell enables precision- ...

R&D and cross-functional operations will be centralized in a single location to enhance collaboration and operational efficiency.Tevogen.AI, strengthened by its partnership with Microsoft, continues to expand. An update on AI and other Company assets, previously estimated to have a market value of $10 billion, is forthcoming.Shareholders will soon receive an update on Tevogen’s goal of finalizing in-house manufacturing capabilities, which are expected to support projected cumulative revenues of $10–14 billi ...

面对火热行情，分歧的声音开始出现。在专业投资人眼中，当前创新药投资的逻辑支撑何在？技术脉络 和投资主线如何把握？估值泡沫的衡量标尺又是什么？中国创新药在全球产业链中的地位究竟如何？证 券时报记者采访了多位医药基金经理，详解创新药的投资主线。 一面是"电子群开始研究创新药"，一面是知名基金经理喊出"创新药的泡沫远比上轮CXO（医药外包） 大"，高歌猛进的"吃药"行情站在了分歧的十字路口。 今年以来，创新药尤其是港股标的强势上涨，带动基金水涨船高，年内收益率最高的汇添富香港优势精 选A大涨78.8%，长城医药产业精选A、永赢医药创新智选A、华安医药生物A等多只医药主题基金年内 涨幅超60%，创新药已然成为今年基金业绩的"胜负手"。 价值发现与价格发现"双击" 华安医药生物股票基金经理桑翔宇进一步详细阐述了中国创新药内部的蝶变，他认为，近期创新药板块 表现比较突出，核心在于市场对于被低估的中国优质创新药资产的价值发现： 一是政策的极大支持。此前全链条支持创新药发展文件给予了创新药企业最大力度的支持，首发定价政 策打开了创新药定价天花板。 二是中国创新药迎来DeepSeek时刻，工程师红利带来产业能力实质性提升。经过 ...